NCT02653599View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

TTP273

DRUG

Placebo

Trial Locations (30)

10459

The Bronx

27265

High Point

27408

Greensboro

28557

Morehead City

30338

Atlanta

32129

Port Orange

32720

DeLand

33014

Miami Lakes

33401

West Palm Beach

33606

Tampa

45246

Cincinnati

48504

Flint

60201

Evanston

68114

Omaha

73069

Norman

73072

Norman

76054

Hurst

77074

Houston

77338

Humble

77450

Katy

78209

San Antonio

78229

San Antonio

78413

Corpus Christi

90057

Los Angeles

90255

Huntington Park

91436

Encino

92626

Costa Mesa

94612

Oakland

95821

Sacramento

99352

Richland

Sponsors

Lead Sponsor

vTv Therapeutics

All Listed Sponsors

lead

vTv Therapeutics

INDUSTRY

NCT02653599 - A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter